News

Ideas That Generate Results

mAbs are one of the most promising protein therapeutic segments. It is also one of the fastest growing segments of the protein therapeutics market. The mAbs market was estimated to be worth around US$ 46 Billion by the end of 2012 and is expected to be worth US$ 77.2 Billion by 2018. The future landscape of the global monoclonal antibody market looks optimistic. mAbs have the advantage of primarily addressing high unmet need in therapy areas such as oncology, arthritis, inflammation and immune disorders, which in turn, boost the existing products on the market.
 
Constant investment by major pharma players in mAbs will continue to boost the Protein Therapeutics market which may reach the mark of US$ 165 Billion by 2018. According to our new research report, “Global Protein Therapeutics Market Outlook 2018”, the growth within the market can also be attributed to increasing disposable income of the individuals and better delivery modes that are being developed.
 
The report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market during the period 2012-2018. It prudently analyzes all the industry segments in an effective manner by focusing on major players and products, recent developments, application support in terms of indications, geographical performance and last but not the least, current and future market size. Moreover, the report provides a brief summary of the recent trends that may have an impact on the future industry performance. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM654.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm